LAS VEGAS, Sept. 24, 2025 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (‘Avant’ or the ‘Company’) today announced the retraction of its press release issued on September 24, 2025, regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova (SGAustria Pte. Ltd.).
The September 24 release contained statements that were issued in error. No binding Joint Venture or License Agreement among Avant Technologies, Art-Islets, and Austrianova has been executed at this time. Accordingly, any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones contained in that release should not be relied upon.
Avant Technologies regrets the confusion caused by the earlier announcement and is committed to providing only accurate and verified information to its shareholders, partners, and the public.
For future updates and accurate Company information, please visit: https://avanttechnologies.com
Forward-Looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Avant Technologies undertakes no obligation to revise or update such statements.
Contact:
Investor Relations
Avant Technologies, Inc.
Email: info@avanttechnologies.com
Logo – https://mma.prnewswire.com/media/2370694/5528268/Avant_Technologies.jpg
SOURCE Avant Technologies Inc.
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia,…
WASHINGTON, D.C. / ACCESS Newswire / January 15, 2026 / The American Medical Informatics Association…
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a…
Multi-year wins underscore sustained specialty-first innovation, workflow depth, and revenue-cycle performance at scale TAMPA, FLORIDA…
First of its kind in the UK as medical cannabis patients get on-demand legal support…
NOTTINGHAM, UK / ACCESS Newswire / January 15, 2026 / First of its kind in…